Overview

Emerging Strategies for Optimizing and Simplifying the Management of Resistant Hypertension

Resistant Hypertension Symposium Highlights

Click the"View Activity" button to view this activity.

View Activity

CME/CE is no longer available for this activity

Format

Symposium Highlights

Time to Complete

1.00 hr(s).

Release Date

October 28, 2022

Expires On

October 28, 2023

Delve into emerging therapies for resistant hypertension in this symposium highlights video. Hear from a multidisciplinary panel of experts discussing the current state of evaluation, diagnosis, and management of resistant hypertension, along with the challenges faced by clinicians. A patient case study and panel discussion provide practical advice for improving patient outcomes within the evolving treatment landscape for a robust and engaging learning experience.

This activity is intended for cardiologists, nephrologists, neurologists, endocrinologists, clinical pharmacists, and other clinicians who evaluate, diagnose, or manage patients with resistant hypertension.

Resistant hypertension (RH) is challenging to treat and is associated with a poor prognosis despite the availability of numerous therapeutic options and detailed guideline recommendations. To address this unmet need, emerging therapies with novel mechanisms of action are being studied and/or have demonstrated their effectiveness in treating RH, with the potential to substantially change future treatment paradigms. To fully realize the potential benefits of these emerging therapies, experts in hypertension from various specialties treating patients with or at risk for RH must understand the challenges that underlie current treatment of RH to formulate effective multispecialty solutions to improve practice now and in the future.

Upon completion of this activity, participants will be able to:

Recognize true resistant hypertension from other types of hypertension, such as apparent resistant hypertension and pseudoresistant hypertension.
Describe guideline-endorsed strategies for the treatment of resistant hypertension in clinical practice.
Discuss clinical data and ongoing studies regarding potential practice-changing emerging pharmacologic therapies directed at treating resistant hypertension.

Pharmacy Learning Objectives

Describe guideline-endorsed strategies for the treatment of resistant hypertension in clinical practice.
Discuss clinical data and ongoing studies regarding potential practice-changing emerging pharmacologic therapies directed at treating resistant hypertension.

Resistant Hypertension: Current Landscape and Emerging Therapies – 25 minutes
Patient Cases: Multidisciplinary Perspectives – 15 minutes
Panel Discussion – 20 minutes

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).

This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker

Sripal Bangalore, MD, MHA
Professor, Department of Medicine
Director, Invasive and Interventional Cardiology, Interventional Director, Adult ECMO and MCS Program
New York University Grossman School of Medicine
New York, NY

John Flack, MD, MPH

Professor and Chair, Sergio Rabinovich Endowed Chair of Internal Medicine

Hypertension Section Chief, Department of Medicine

Southern Illinois University

Springfield, IL

Sandra Taler, MD

Professor of Medicine

Division of Nephrology and Hypertension, Dept. of Internal Medicine

Mayo Clinic

Rochester, MN

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

The following financial relationships have been provided:

Sripal Bangalore, MD (Faculty)

Advisory Board: Amgen, Merck, Pfizer

John Flack, MD, MPH (Faculty)

Consulting Agreements: Amgen, FibroGen, Glaxo Smith Kline, Janssen, Merck

Sources of Funding for Research: Indorsia, ReCor Medical, Quantam Genomics, Vascular Dynamics

Other: Teva (Expert Witness)

Sandra Taler, MD (Faculty) has no financial relationships to disclose.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Empagliflozin, dapagliflozin, canagliflozin, sacubitril/valsartan combination, firibastat, and aprocitentan are not approved for the treatment of resistant hypertension. No device-based therapies are approved for the treatment of resistant hypertension.

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires all speakers to disclose that a product is not labeled for the use under discussion.

Pharmacists should consult with their state pharmacy on pharmacist vaccination authority included within their scope of practice.

This activity will take approximately 1 hour to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, please contact Ty Jackson at tjackson@achlcme.org.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been approved for 1.0 contact hour.

ACPE Universal Activity Number: 0396-0000-22-061-H01-P

Activity Type(s): Knowledge

CPE credit will be submitted to CPE Monitor® on the first business day of each month.

Tyescia Jackson
tjackson@achlcme.org

Overview

Emerging Strategies for Optimizing and Simplifying the Management of Resistant Hypertension

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Meeting Schedule

Provider Information

Supporter Information

Hardware and Software Requirement

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities